Parker Institute for Cancer Immunotherapy Adds Key Leader to Drive Clinical Research Efforts

Parker Institute for Cancer Immunotherapy Adds Key Leader to Drive Clinical Research Efforts

SAN FRANCISCO, June 15, 2016 — The Parker Institute for Cancer Immunotherapy has recruited Ramy Ibrahim, M.D. as its new Vice President, Clinical Development. Ramy was most recently employed by AstraZeneca where he led the clinical team developing multiple immunotherapies. Ramy Ibrahim is a trained medical oncologist, who conducted bench and clinical immunotherapy research at the National Cancer Institute in Bethesda, MD.

“Ramy has been a pioneer and leader in cancer immunotherapy and will lead the Parker Institute as we grow our collaborative clinical enterprise with our institutional leaders at Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California, Los Angeles, the University of California, San Francisco, the University of Pennsylvania and The University of Texas MD Anderson Cancer Center.” said Jeffrey Bluestone, CEO and President, Parker Institute for Cancer Immunotherapy.

Prior to joining the Parker Institute, Ramy served first as Senior Medical Director and most recently, the Clinical Vice President, Immune-Oncology, Global Medicines Development at MedImmune/AstraZeneca where he built and led the clinical team working on the registrational studies both with single drug and combination therapies.  As a member of the Bristol Meyers Squib Immuno-oncology program, he served on the BMS Yervoy (ipilimumab) clinical team supporting the program from early phase II through multiple global launches of the first FDA-approved Immune Checkpoint inhibitor. In addition, he played a key role in early development for nivolumab (PD-1), PDL1, and CD137 antibody.

Throughout his career, Ramy has been involved with global cancer immunotherapy societies such as Society of Immunotherapy for Cancer (SITC), Ludwig Institute, and the Cancer Research Institute and Cancer Immunotherapy Trials Network (CITN).

Ramy joins the leadership team at Parker Institute led by CEO and President Jeffrey Bluestone, Ph.D. and includes Cheryl Selinsky, Ph.D., Vice President, Research Operations; Adam Kolom, Vice President, Business Development and Strategic Partnership; Jennifer Haslip, Vice President, Communications; Melinda Griffith, J.D., Chief Legal Counsel; Nikesh Kotecha, Vice President, Informatics; Fred Ramsell, Ph.D., Scientific Program Head and Dave Hoffman, Ph.D., J.D, Executive Director, Intellectual Property.

About the Parker Institute for Cancer Immunotherapy

The Parker Institute for Cancer Immunotherapy brings together the best scientists, clinicians, and industry partners to build a smarter and more coordinated cancer immunotherapy research effort. The Parker Institute is an unprecedented collaboration between the country’s leading immunologists and cancer centers: Memorial Sloan Kettering Cancer Center, Stanford Medicine, the University of California, Los Angeles, the University of California, San Francisco, the University of Pennsylvania and The University of Texas MD Anderson Cancer Center. The Parker Institute was created through a $250 million grant from The Parker Foundation.

The Parker Institute’s goal is to accelerate the development of breakthrough immune therapies capable of turning cancer into a curable disease by ensuring the coordination and collaboration of the field’s top researchers, and quickly turning their findings into patient treatments. The Parker Institute network brings together:

• 6 centers

• 40+ Labs

• 300+ of the nation’s top researchers focused on treating the deadliest cancers

For more information, visit www.parkerici.org and follow us on Facebook: www.facebook.com/ParkerICI and on Twitter: @parkerICI

Contact:

Jennifer Haslip
Vice President of Communications, The Parker Institute for Cancer Immunotherapy
(415) 930-4346
jhaslip@parkerici.org